INVESTOR DEADLINE: Aurinia Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – AUPH

Author's Avatar
May 14, 2022

The law firm of Robbins+Geller+Rudman+%26amp%3B+Dowd+LLP announces that purchasers or acquirers of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) securities between May 7, 2021 and February 25, 2022, both dates inclusive (the “Class Period”) have until June 14, 2022 to seek appointment as lead plaintiff in Ortmann v. Aurinia Pharmaceuticals Inc., No. 22-cv-02185. Commenced in the Eastern District of New York on April 15, 2022, the Aurinia class action lawsuit charges Aurinia and certain of its top executive officers with violations of the Securities Exchange Act of 1934.